niacinamide has been researched along with Autoimmune Diabetes in 129 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this cohort of type 1 diabetes patients with mild-to-moderate CAN, a combination antioxidant treatment regimen did not prevent progression of CAN, had no beneficial effects on myocardial perfusion or DPN, and may have been detrimental." | 2.78 | Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. ( Brown, MB; Feldman, EL; Mehta, M; Plunkett, CD; Pop-Busui, R; Raffel, DM; Stevens, MJ; White, EA, 2013) |
| "At the dosage used, calcitriol has a modest effect on residual pancreatic beta-cell function and only temporarily reduces the insulin dose." | 2.72 | The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). ( Anguissola, GB; Bizzarri, C; Cavallo, MG; Crinò, A; Di Stasio, E; Guglielmi, C; Manfrini, S; Matteoli, MC; Patera, IP; Pitocco, D; Pozzilli, P; Spera, S; Suraci, C; Visalli, N, 2006) |
| "Nicotinamide prevents autoimmune diabetes in animal models, possibly through inhibition of the DNA repair enzyme poly-ADP-ribose polymerase and prevention of beta-cell NAD depletion." | 2.71 | European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. ( Bingley, PJ; Collier, T; Emmett, CL; Gale, EA, 2004) |
| "Recent onset type 1 diabetes patients (n=64, mean age 8." | 2.71 | A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). ( Beretta Anguissola, G; Bizzarri, C; Corbi, S; Crinò, A; Manca Bitti, ML; Manfrini, S; Matteoli, MC; Mesturino, C; Patera, IP; Pitocco, D; Pozzilli, P; Schiaffini, R; Spera, S; Suraci, C; Visalli, N, 2004) |
| "Individuals at high risk for developing IDDM within 3 years were identified by screening the siblings (age 3-12 years) of patients with IDDM for the presence of high titer (> or =20 Juvenile Diabetes Foundation [JDF] U) islet cell antibodies." | 2.69 | The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. ( Giani, G; Haastert, B; Heinze, E; Klinghammer, A; Kolb, H; Lampeter, EF; Scherbaum, WA, 1998) |
| "First degree relatives of type 1 diabetes children attending paediatric clinics in Norway were recruited." | 2.69 | [Genetic and immunologic risks for development of type 1 diabetes--experiences from an intervention trial]. ( Dahl-Jørgensen, K; Joner, G; Nicol-Smith, L; Rønningen, KS; Søvik, O; Torjesen, PA; Undlien, DE, 2000) |
| "For the first time, we studied 27 type 1 diabetes patients treated with NA for 12 months and then followed up for 1 year after discontinuance of NA." | 2.68 | Adjuvant therapy in recent onset type 1 diabetes at diagnosis and insulin requirement after 2 years. ( Baroni, MG; Boccuni, ML; Buzzetti, R; Cavallo, MG; Fioriti, E; Mesturino, C; Pozzilli, P; Signore, A; Valente, L; Visalli, N, 1995) |
| "Eighty-four IDDM patients between 5 and 35 years of age (mean age 15." | 2.68 | Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study) ( Amoretti, R; Baroni, MG; Buzzetti, R; Cavallo, MG; Crinò, A; De Mattia, G; Faldetta, MR; Fiori, R; Fioriti, E; Giovannini, C; Lucentini, L; Matteoli, MC; Mesturino, C; Multari, G; Paci, F; Pisano, L; Pozzilli, P; Romiti, A; Signore, A; Sulli, N; Suppa, M; Suraci, C; Suraci, MT; Teodonio, C; Visalli, N, 1997) |
| "These data suggest that treatment of Type 1 diabetes with nicotinamide at diagnosis is associated with a moderate increase of C-peptide secretion recovery." | 2.66 | Effect of nicotinamide therapy upon B-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. ( Casamitjana, R; Gomis, R; Mendola, G, 1989) |
| "Since type 1 diabetes is an immunologically mediated disease, immune intervention should alter the natural history of the disease." | 2.49 | Primary and secondary prevention of Type 1 diabetes. ( Skyler, JS, 2013) |
| "Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells." | 2.48 | Immunotherapies in diabetes mellitus type 1. ( Gupta, S, 2012) |
| "Prevention of type 1 diabetes in high risk individuals presents with both positive and negative aspects." | 2.42 | [Prevention of type 1 diabetes: what have we achieved? What should we say and propose next to families?]. ( Mattei, C; Nervi, S; Valéro, R; Vialettes, B, 2003) |
| " High-dose nicotinamide should still, however, be considered as a drug with toxic potential at adult doses in excess of 3 gm/day and unsupervised use should be discouraged." | 2.41 | Safety of high-dose nicotinamide: a review. ( Bingley, PJ; Douek, IF; Gale, EA; Gillmor, HA; Knip, M; McLean, AE; Moore, WP, 2000) |
| "In recent-onset type 1 diabetes, nicotinamide administration improves beta-cell function, without significantly decreased insulin requirements." | 2.40 | Nicotinamide in type 1 diabetes. Mechanism of action revisited. ( Burkart, V; Kolb, H, 1999) |
| "This ability to predict future cases of IDDM raises the possibility of intervention to prevent the disease." | 2.39 | Nicotinamide and diabetes prevention. ( Behme, MT, 1995) |
| "IDDM is caused by an immune-mediated destruction of the insulin-producing beta cells." | 2.39 | [Nicotinamide and prevention of insulin-dependent diabetes mellitus. Rationale, effects, toxicology and clinical experiences. ENDIT Group]. ( Andersen, HU; Pociot, F; Reimers, JI, 1994) |
| "Moreover, after the clinical onset of IDDM, most patients experience a transitory period of improved insulin secretion." | 2.38 | Repair of pancreatic beta-cells. A relevant phenomenon in early IDDM? ( Eizirik, DL; Palmer, JP; Sandler, S, 1993) |
| "Type 1 diabetes is considered to be a chronic autoimmune disease characterized by gradual beta-cell destruction mediated by autoreactive T-lymphocytes during an asymptomatic prediabetic phase of varying duration." | 2.38 | [Can type-1 diabetes in children be prevented?]. ( Knip, M, 1992) |
| "The effects of Type 1 diabetes mellitus and of exposure to mainstream cigarette smoke on noradrenaline (NA) uptake and its subsequent metabolism by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) in the perfused lungs of rats were examined." | 1.28 | The effects of type 1 diabetes mellitus and of tobacco smoke on dissipation of catecholamines in pulmonary endothelial cells--a non-neuronal site of uptake1. ( Bryan-Lluka, LJ; McKee, GJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (8.53) | 18.7374 |
| 1990's | 56 (43.41) | 18.2507 |
| 2000's | 48 (37.21) | 29.6817 |
| 2010's | 11 (8.53) | 24.3611 |
| 2020's | 3 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Faingold, MC | 1 |
| Luquez, C | 1 |
| Oviedo, A | 1 |
| Puchulu, F | 1 |
| Re, M | 1 |
| Torres-Méndez, JK | 1 |
| Niño-Narvión, J | 1 |
| Martinez-Santos, P | 1 |
| Diarte-Añazco, EMG | 1 |
| Méndez-Lara, KA | 1 |
| Del Olmo, TV | 1 |
| Rotllan, N | 1 |
| Julián, MT | 1 |
| Alonso, N | 1 |
| Mauricio, D | 1 |
| Camacho, M | 1 |
| Muñoz, JP | 1 |
| Rossell, J | 1 |
| Julve, J | 1 |
| Neyshaburinezhad, N | 1 |
| Seidabadi, M | 1 |
| Rouini, M | 1 |
| Lavasani, H | 1 |
| Foroumadi, A | 1 |
| Ardakani, YH | 1 |
| Kildegaard, J | 1 |
| Buckley, ST | 1 |
| Nielsen, RH | 1 |
| Povlsen, GK | 1 |
| Seested, T | 1 |
| Ribel, U | 1 |
| Olsen, HB | 1 |
| Ludvigsen, S | 1 |
| Jeppesen, CB | 1 |
| Refsgaard, HHF | 1 |
| Bendtsen, KM | 1 |
| Kristensen, NR | 1 |
| Hostrup, S | 1 |
| Sturis, J | 1 |
| Pop-Busui, R | 1 |
| Stevens, MJ | 1 |
| Raffel, DM | 1 |
| White, EA | 1 |
| Mehta, M | 1 |
| Plunkett, CD | 1 |
| Brown, MB | 1 |
| Feldman, EL | 1 |
| Fernandez, IC | 1 |
| Del Carmen Camberos, M | 1 |
| Passicot, GA | 1 |
| Martucci, LC | 1 |
| Cresto, JC | 1 |
| Arthur, JF | 1 |
| Shen, Y | 1 |
| Chen, Y | 1 |
| Qiao, J | 1 |
| Ni, R | 1 |
| Lu, Y | 1 |
| Andrews, RK | 1 |
| Gardiner, EE | 1 |
| Cheng, J | 1 |
| Simmons, K | 1 |
| Michels, AW | 1 |
| Furman, BL | 1 |
| Folwarczna, J | 1 |
| Janas, A | 1 |
| Pytlik, M | 1 |
| Cegieła, U | 1 |
| Śliwiński, L | 1 |
| Krivošíková, Z | 1 |
| Štefíková, K | 1 |
| Gajdoš, M | 1 |
| Skyler, JS | 4 |
| Jung, DY | 1 |
| Park, JB | 1 |
| Joo, SY | 1 |
| Joh, JW | 1 |
| Kwon, CH | 1 |
| Kwon, GY | 1 |
| Kim, SJ | 1 |
| Neshati, Z | 1 |
| Matin, MM | 1 |
| Bahrami, AR | 1 |
| Moghimi, A | 1 |
| Long, AE | 1 |
| Gooneratne, AT | 1 |
| Rokni, S | 1 |
| Williams, AJ | 1 |
| Bingley, PJ | 5 |
| Gupta, S | 1 |
| Kobayashi, T | 1 |
| Maruyama, T | 1 |
| Miyagawa, J | 2 |
| Hori, Y | 1 |
| Rulifson, IC | 1 |
| Tsai, BC | 1 |
| Heit, JJ | 1 |
| Cahoy, JD | 1 |
| Kim, SK | 1 |
| Philips, JC | 1 |
| Scheen, AJ | 1 |
| Couzin, J | 1 |
| Suarez-Pinzon, WL | 1 |
| Mabley, JG | 1 |
| Power, R | 1 |
| Szabó, C | 1 |
| Rabinovitch, A | 1 |
| ROGOZINSKI, R | 1 |
| Daaboul, J | 1 |
| Schatz, D | 1 |
| Vialettes, B | 3 |
| Valéro, R | 1 |
| Mattei, C | 1 |
| Nervi, S | 1 |
| Wang, PH | 1 |
| Gale, EA | 5 |
| Emmett, CL | 1 |
| Collier, T | 1 |
| Vendrame, F | 1 |
| Gottlieb, PA | 1 |
| Liu, HK | 1 |
| Green, BD | 1 |
| Flatt, PR | 1 |
| McClenaghan, NH | 1 |
| McCluskey, JT | 1 |
| Crinò, A | 4 |
| Schiaffini, R | 2 |
| Manfrini, S | 3 |
| Mesturino, C | 3 |
| Visalli, N | 8 |
| Beretta Anguissola, G | 1 |
| Suraci, C | 3 |
| Pitocco, D | 3 |
| Spera, S | 3 |
| Corbi, S | 1 |
| Matteoli, MC | 4 |
| Patera, IP | 2 |
| Manca Bitti, ML | 1 |
| Bizzarri, C | 2 |
| Pozzilli, P | 14 |
| Segev, H | 1 |
| Fishman, B | 1 |
| Ziskind, A | 1 |
| Shulman, M | 1 |
| Itskovitz-Eldor, J | 1 |
| Hyppönen, E | 1 |
| Kuntz, E | 1 |
| Pinget, M | 1 |
| Damgé, P | 1 |
| Karlsson Faresjö, MG | 1 |
| Ludvigsson, J | 2 |
| Reimers, JI | 4 |
| Larsen, CM | 1 |
| Mandrup-Poulsen, TR | 1 |
| Gosteli, J | 1 |
| Thomas, MC | 1 |
| Jerums, G | 1 |
| Tsalamandris, C | 1 |
| Macisaac, R | 1 |
| Panagiotopoulos, S | 1 |
| Cooper, ME | 1 |
| Ciampalini, P | 1 |
| Suraci, MC | 1 |
| Patera, P | 1 |
| Buzzetti, R | 5 |
| Guglielmi, C | 2 |
| Costanza, F | 1 |
| Fioriti, E | 4 |
| Olmos, PR | 1 |
| Hodgson, MI | 1 |
| Maiz, A | 1 |
| Manrique, M | 1 |
| De Valdés, MD | 1 |
| Foncea, R | 1 |
| Acosta, AM | 1 |
| Emmerich, MV | 1 |
| Velasco, S | 1 |
| Muñiz, OP | 1 |
| Oyarzún, CA | 1 |
| Claro, JC | 1 |
| Bastías, MJ | 1 |
| Toro, LA | 1 |
| Lo, HC | 1 |
| Tsai, FA | 1 |
| Wasser, SP | 1 |
| Yang, JG | 1 |
| Huang, BM | 1 |
| Hedman, M | 1 |
| Faresjö, MK | 1 |
| Kamal, M | 1 |
| Abbasy, AJ | 1 |
| Muslemani, AA | 1 |
| Bener, A | 1 |
| Ichii, H | 1 |
| Wang, X | 1 |
| Messinger, S | 1 |
| Alvarez, A | 1 |
| Fraker, C | 1 |
| Khan, A | 1 |
| Kuroda, Y | 1 |
| Inverardi, L | 1 |
| Goss, JA | 1 |
| Alejandro, R | 1 |
| Ricordi, C | 1 |
| Cabrera-Rode, E | 1 |
| Molina, G | 1 |
| Arranz, C | 1 |
| Vera, M | 1 |
| González, P | 1 |
| Suárez, R | 1 |
| Prieto, M | 1 |
| Padrón, S | 1 |
| León, R | 1 |
| Tillan, J | 1 |
| García, I | 1 |
| Tiberti, C | 1 |
| Rodríguez, OM | 1 |
| Gutiérrez, A | 1 |
| Fernández, T | 1 |
| Govea, A | 1 |
| Hernández, J | 1 |
| Chiong, D | 1 |
| Domínguez, E | 1 |
| Di Mario, U | 1 |
| Díaz-Díaz, O | 1 |
| Díaz-Horta, O | 1 |
| Di Stasio, E | 1 |
| Anguissola, GB | 1 |
| Cavallo, MG | 5 |
| Boucher, BJ | 1 |
| Chianelli, M | 1 |
| Parisella, MG | 1 |
| Mather, SJ | 1 |
| D'Alessandria, C | 1 |
| Signore, A | 5 |
| Mahon, JL | 1 |
| Sherr, J | 1 |
| Sosenko, J | 1 |
| Herold, KC | 1 |
| Eizirik, DL | 3 |
| Migliorini, RH | 1 |
| Rossini, AA | 1 |
| Mordes, JP | 1 |
| Gallina, DL | 1 |
| Like, AA | 1 |
| Baroni, MG | 4 |
| Boccuni, ML | 3 |
| Fava, D | 1 |
| Gragnoli, C | 1 |
| Andreani, D | 4 |
| Sandler, S | 2 |
| Welsh, N | 2 |
| Bendtzen, K | 1 |
| Hellerström, C | 2 |
| Eisenbarth, GS | 2 |
| Verge, CF | 1 |
| Allen, H | 1 |
| Rewers, MJ | 1 |
| Behme, MT | 1 |
| Valente, L | 1 |
| Kretowski, A | 3 |
| Kinalska, I | 3 |
| Kolb, H | 6 |
| Taboga, C | 1 |
| Tonutti, L | 1 |
| Noacco, C | 1 |
| Mandrup-Poulsen, T | 1 |
| Andersen, HU | 3 |
| Pociot, F | 3 |
| Karlsen, AE | 1 |
| Bjerre, U | 1 |
| Nerup, J | 2 |
| Lucentini, L | 2 |
| Kuntschen, F | 1 |
| Zumsteg, U | 1 |
| Elliott, RB | 4 |
| Pilcher, CC | 1 |
| Stewart, A | 1 |
| Fergusson, D | 1 |
| McGregor, MA | 1 |
| Alberti, KG | 1 |
| Haastert, B | 2 |
| Giani, G | 2 |
| Lampeter, EF | 2 |
| Palmer, JP | 3 |
| Reddy, S | 4 |
| Bibby, NJ | 2 |
| Wu, D | 1 |
| Swinney, C | 1 |
| Barrow, G | 1 |
| Margulis, B | 1 |
| Borg, LA | 1 |
| Wiklund, HJ | 1 |
| Saldeen, J | 1 |
| Flodström, M | 1 |
| Mello, MA | 1 |
| Andersson, A | 1 |
| Pipeleers, DG | 1 |
| Dedov, II | 1 |
| Gorelysheva, VA | 1 |
| Romanovskaia, GA | 1 |
| Filippov, IK | 1 |
| Smirnova, OM | 1 |
| Schernthaner, G | 1 |
| Greenbaum, CJ | 1 |
| Kahn, SE | 1 |
| Browne, PD | 1 |
| Schwertner, R | 1 |
| Rabl, W | 1 |
| Ziegler, AG | 1 |
| Spinas, GA | 1 |
| Hu, Y | 1 |
| Wang, Y | 1 |
| Wang, L | 1 |
| Zhang, H | 2 |
| Zhao, B | 1 |
| Zhang, A | 1 |
| Li, Y | 1 |
| Kim, JY | 1 |
| Chi, JK | 1 |
| Kim, EJ | 1 |
| Park, SY | 1 |
| Kim, YW | 1 |
| Lee, SK | 1 |
| Thivolet, C | 1 |
| Fiori, R | 1 |
| Romiti, A | 1 |
| Giovannini, C | 1 |
| Teodonio, C | 1 |
| Paci, F | 1 |
| Amoretti, R | 1 |
| Pisano, L | 1 |
| Multari, G | 1 |
| Suppa, M | 1 |
| Sulli, N | 1 |
| De Mattia, G | 1 |
| Faldetta, MR | 1 |
| Suraci, MT | 1 |
| Cunningham, JJ | 1 |
| Klinghammer, A | 1 |
| Scherbaum, WA | 1 |
| Heinze, E | 1 |
| Knip, M | 3 |
| Akerblom, HK | 1 |
| Weinand, S | 1 |
| Jahr, H | 1 |
| Hering, BJ | 1 |
| Federlin, K | 1 |
| Bretzel, RG | 1 |
| Burkart, V | 1 |
| Myśliwiec, J | 2 |
| Szelachowska, M | 2 |
| Kinalski, M | 2 |
| O'Brien, BA | 1 |
| Harmon, BV | 1 |
| Cameron, DP | 1 |
| Allan, DJ | 1 |
| Vidal, J | 1 |
| Fernández-Balsells, M | 1 |
| Sesmilo, G | 1 |
| Aguilera, E | 1 |
| Casamitjana, R | 2 |
| Gomis, R | 2 |
| Conget, I | 1 |
| Undlien, DE | 1 |
| Joner, G | 1 |
| Dahl-Jørgensen, K | 1 |
| Rønningen, KS | 1 |
| Nicol-Smith, L | 1 |
| Torjesen, PA | 1 |
| Søvik, O | 1 |
| Douek, IF | 1 |
| Moore, WP | 1 |
| Gillmor, HA | 1 |
| McLean, AE | 1 |
| Schatz, DA | 1 |
| Karanam, M | 1 |
| Robinson, E | 1 |
| Peck, AB | 1 |
| Cornelius, JG | 1 |
| Chaudhari, M | 1 |
| Shatz, D | 1 |
| Ramiya, VK | 1 |
| Young, M | 1 |
| Manna, R | 1 |
| Migliore, A | 1 |
| Martin, LS | 1 |
| Ferrara, E | 1 |
| Ponte, E | 1 |
| Marietti, G | 1 |
| Scuderi, F | 1 |
| Cristiano, G | 1 |
| Ghirlanda, G | 1 |
| Gambassi, G | 1 |
| Chase, P | 1 |
| Dupre, J | 1 |
| Mahon, J | 1 |
| Ehrlich, R | 1 |
| Gale, E | 1 |
| Lampeter, E | 1 |
| Kolb-Bachofen, V | 1 |
| Michalková, D | 1 |
| Kolár, J | 1 |
| Jancová, E | 1 |
| Barák, L | 1 |
| Sílesová, J | 1 |
| Lewis, CM | 1 |
| Canafax, DM | 1 |
| Sprafka, JM | 1 |
| Barbosa, JJ | 1 |
| Tanaka, Y | 1 |
| Kashiwagi, A | 1 |
| Shigeta, Y | 1 |
| McNally, PG | 1 |
| Feehally, J | 1 |
| Walls, J | 1 |
| Chase, HP | 2 |
| Bryan-Lluka, LJ | 1 |
| McKee, GJ | 1 |
| Butler-Simon, N | 1 |
| Garg, S | 1 |
| McDuffie, M | 1 |
| Hoops, SL | 1 |
| O'Brien, D | 1 |
| Mendola, G | 1 |
| Vague, P | 2 |
| Picq, R | 1 |
| Bernal, M | 1 |
| Lassmann-Vague, V | 2 |
| Herskowitz, RD | 1 |
| Jackson, RA | 1 |
| Soeldner, JS | 1 |
| Vallo, JJ | 1 |
| Nakajima, H | 1 |
| Yamada, K | 1 |
| Hanafusa, T | 1 |
| Fujino-Kurihara, H | 1 |
| Miyazaki, A | 1 |
| Saitoh, R | 1 |
| Minami, Y | 1 |
| Kono, N | 1 |
| Nonaka, K | 1 |
| Handfield-Jones, S | 2 |
| Jones, SK | 1 |
| Peachey, RD | 1 |
| Jones, S | 1 |
| Peachey, R | 1 |
| Obrosova, IG | 1 |
| Kirput', SN | 1 |
| Ostrovskiĭ, IuM | 1 |
| Larin, FS | 1 |
| Efimov, AS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Oxidative Stress and Cardiovascular Denervation in Diabetes: An Interventional Trial[NCT00116207] | Phase 3 | 44 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| TrialNet Pathway to Prevention of T1D[NCT00097292] | 75,000 participants (Anticipated) | Observational | 2004-02-29 | Recruiting | |||
| Comparison of Nicotinamide and Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients[NCT01011699] | Phase 3 | 176 participants (Actual) | Interventional | 2010-01-31 | Terminated (stopped due to Financial problem) | ||
| Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib[NCT02416739] | Phase 2/Phase 3 | 110 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Clinical Study to Evaluate the Efficacy of 1,25(OH)2D3 (Calcitriol) Versus Placebo in Recent Onset Type 1 Diabetes(IMDIAB XIII)[NCT01120119] | Phase 2 | 0 participants | Interventional | Completed | |||
| Trial to Reduce IDDM in the Genetically at Risk (TRIGR): the Pilot Study[NCT00570102] | Phase 2 | 230 participants (Actual) | Interventional | 1995-02-28 | Completed | ||
| Three-Day Dosing NAD + Study[NCT03707652] | 8 participants (Actual) | Interventional | 2018-03-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
High Sensitivity CRP (nmol/L) (NCT00116207)
Timeframe: 24 months
| Intervention | nmol/L (Mean) |
|---|---|
| ORAL ANTIOXIDANT | 17.51 |
| Placebo | 16.95 |
ng of 8-epi prostaglandin F2alpha /G creatinine assessed in 24 hour urine collection (NCT00116207)
Timeframe: 24 months
| Intervention | ng/G creatinine (Mean) |
|---|---|
| ORAL ANTIOXIDANT | 2.92 |
| Placebo | 2.09 |
"Distal defects in [11C]meta-hydroxyephedrine ([11C]HED) retention involving at least 10 % of the left ventricle was used to define Cardiac Autonomic Neuropathy (CAN). The retention index (RI) is the unit of measure and is expressed as [11C]HEDblood min -1[ml tissue]-1~PET Data of Randomized Subjects at Baseline and 24-Months~The primary outcome was the change in the global [11C]HED RI = measure of cardiac innervation at 24 months in participants taking the active drug compared with those on placebo." (NCT00116207)
Timeframe: Baseline, 24 months
| Intervention | Retention index (Mean) | |
|---|---|---|
| BASELINE | 24 MONTHS | |
| ORAL ANTIOXIDANT | 0.081 | 0.070 |
| Placebo | 0.073 | 0.074 |
global myocardial blood flow reserve as a measure of endothelial function. Measured by PET using [13N]ammonia at rest and during adenosine stimulated coronary vasodilation. (NCT00116207)
Timeframe: Baseline, 24 months
| Intervention | ratio (rest:stress) (Mean) | |
|---|---|---|
| BASELINE | 24 MONTH | |
| ORAL ANTIOXIDANT | 2.95 | 3.02 |
| Placebo | 2.94 | 3.22 |
36 reviews available for niacinamide and Autoimmune Diabetes
| Article | Year |
|---|---|
Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.
Topics: Abatacept; Antibodies, Monoclonal, Humanized; Autoantibodies; Autoimmune Diseases; Diabetes Mellitus | 2014 |
Update on worldwide efforts to prevent type 1 diabetes.
Topics: Diabetes Mellitus, Type 1; Global Health; Humans; Models, Biological; Niacinamide; Randomized Contro | 2008 |
Immunotherapies in diabetes mellitus type 1.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine | 2012 |
Primary and secondary prevention of Type 1 diabetes.
Topics: Abatacept; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Autoantibodies; Child; Child, Presc | 2013 |
[Multicenter randomized trial on prevention of type 1 diabetes].
Topics: Autoantibodies; Biomarkers; Diabetes Mellitus, Type 1; Disease Progression; Glutamate Decarboxylase; | 2002 |
[Pharmacotherapies for type 1 diabetes mellitus].
Topics: Adjuvants, Immunologic; Animals; Biguanides; Chaperonin 60; Diabetes Mellitus, Type 1; Glycoside Hyd | 2002 |
[Regenerative medicine in diabetes by beta cell therapy and promotion of beta cell growth and differentiation].
Topics: Animals; Antigens, Neoplasm; Betacellulin; Biomarkers, Tumor; Cell Differentiation; Cell Division; D | 2002 |
Overview of prevention and intervention trials for type 1 diabetes.
Topics: Animals; Antibodies, Monoclonal; Antioxidants; Autoantigens; Clinical Trials as Topic; Cytokines; Di | 2003 |
[Prevention of type 1 diabetes: what have we achieved? What should we say and propose next to families?].
Topics: Autoantibodies; Biomarkers; Diabetes Mellitus, Type 1; Genetic Markers; Humans; Insulin; Niacinamide | 2003 |
Prediabetes: prediction and prevention trials.
Topics: Animals; Diabetes Mellitus, Type 1; Humans; Insulin; Niacinamide; Prediabetic State; Vitamin D | 2004 |
Micronutrients and the risk of type 1 diabetes: vitamin D, vitamin E, and nicotinamide.
Topics: Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Humans; Micronutrients; Niacinamide; Ris | 2004 |
Prediction and prevention of type 1 diabetes: progress, problems, and prospects.
Topics: Diabetes Mellitus, Type 1; Fatty Acids, Omega-3; Female; Forecasting; Humans; Hypoglycemic Agents; I | 2007 |
Prevention of type 1 diabetes: the time has come.
Topics: Autoantibodies; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Epitopes; Glucose Intolerance; | 2008 |
Nicotinamide and diabetes prevention.
Topics: Child; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Humans; New Zealand; Niacinamide; Risk F | 1995 |
[Influence of nicotinamide on the course of insulin-dependent diabetes mellitus].
Topics: Diabetes Mellitus, Type 1; Humans; Niacinamide; Treatment Outcome | 1994 |
Immune intervention in type I diabetes mellitus--current clinical and experimental approaches.
Topics: Adjuvants, Immunologic; Cell Survival; Diabetes Mellitus, Type 1; Endocrinology; Humans; Immunosuppr | 1994 |
Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus.
Topics: Animals; Autoimmunity; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Free Radicals; Hu | 1993 |
[Nicotinamide and prevention of insulin-dependent diabetes mellitus. Rationale, effects, toxicology and clinical experiences. ENDIT Group].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Humans; Islets of Langerhans; Niacinam | 1994 |
The potential role of nicotinamide in the secondary prevention of IDDM.
Topics: Diabetes Mellitus, Type 1; Humans; Nervous System Diseases; Niacinamide; Psychotic Disorders; Skin D | 1993 |
Repair of pancreatic beta-cells. A relevant phenomenon in early IDDM?
Topics: Animals; Diabetes Mellitus, Type 1; Dietary Proteins; Glucose; Humans; Islets of Langerhans; Mice; M | 1993 |
Progress in the immunointervention of type-1 diabetes mellitus.
Topics: BCG Vaccine; Cyclosporine; Diabetes Mellitus, Type 1; Humans; Immunotherapy; Insulin; Niacinamide | 1995 |
Molecular mechanisms of beta-cell destruction in IDDM: the role of nicotinamide.
Topics: Diabetes Mellitus, Type 1; Humans; Islets of Langerhans; Niacinamide; Prediabetic State | 1996 |
Nicotinamide: potential for the prevention of type 1 diabetes?
Topics: Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 1; Europe; Humans; Islets of Langerhans | 1996 |
Prevention of insulin-dependent diabetes: where are we now?
Topics: Administration, Oral; Animals; Antigens; Diabetes Mellitus, Type 1; Finland; Humans; Immunosuppressi | 1996 |
Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists.
Topics: Adolescent; Adult; C-Peptide; Child; Diabetes Mellitus, Type 1; Humans; Insulin; Insulin Secretion; | 1996 |
[Insulin dependent diabetes (type I)--prophylaxis possibilities].
Topics: Diabetes Mellitus, Type 1; Early Intervention, Educational; Humans; Immunotherapy; Insulin; Niacinam | 1996 |
[Immunoprevention of Type I diabetes mellitus].
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 1; Free Radical Scavengers; Histocompatibilit | 1996 |
[Pre-diabetes type 1. Evaluation of current clinical trials].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Humans; Insulin; Islets of Langerhans; Niacinam | 1997 |
Micronutrients as nutriceutical interventions in diabetes mellitus.
Topics: Antioxidants; Ascorbic Acid; Blood Glucose; Diabetes Mellitus, Type 1; Humans; Micronutrients; Miner | 1998 |
Prevention of insulin-dependent diabetes mellitus 1998.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Niacinami | 1998 |
IDDM prevention trials in progress--a critical assessment.
Topics: Cell Death; Clinical Protocols; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Family; Feeding | 1998 |
Nicotinamide in type 1 diabetes. Mechanism of action revisited.
Topics: ADP Ribose Transferases; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Humans; Islets of Langer | 1999 |
Safety of high-dose nicotinamide: a review.
Topics: Abnormalities, Drug-Induced; Adenoma, Islet Cell; Animals; Chemical and Drug Induced Liver Injury; D | 2000 |
Safety of high-dose nicotinamide: a review.
Topics: Abnormalities, Drug-Induced; Adenoma, Islet Cell; Animals; Chemical and Drug Induced Liver Injury; D | 2000 |
Safety of high-dose nicotinamide: a review.
Topics: Abnormalities, Drug-Induced; Adenoma, Islet Cell; Animals; Chemical and Drug Induced Liver Injury; D | 2000 |
Safety of high-dose nicotinamide: a review.
Topics: Abnormalities, Drug-Induced; Adenoma, Islet Cell; Animals; Chemical and Drug Induced Liver Injury; D | 2000 |
Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT).
Topics: Diabetes Mellitus, Type 1; Humans; Insulin; Mass Screening; Multicenter Studies as Topic; Niacinamid | 2001 |
Type 1 (insulin-dependent) diabetes mellitus and nitric oxide.
Topics: Animals; Cell Death; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Free Radicals; Huma | 1992 |
[Can type-1 diabetes in children be prevented?].
Topics: Child; Diabetes Mellitus, Type 1; Forecasting; Humans; Infant; Infant Food; Milk Proteins; Niacinami | 1992 |
32 trials available for niacinamide and Autoimmune Diabetes
| Article | Year |
|---|---|
Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allopurinol; Antioxidants; Diabetes Mellitus, Type 1; Diabetic Neuropathies | 2013 |
[Info-congress. Study of the prevention of type 1 diabetes with nicotinamide: positive lessons of a negative clinical trial (ENDIT)].
Topics: Diabetes Mellitus, Type 1; Evidence-Based Medicine; Humans; Multicenter Studies as Topic; Niacinamid | 2002 |
Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT).
Topics: Adolescent; Adult; Autoantibodies; Child; Child, Preschool; Diabetes Mellitus, Type 1; Double-Blind | 2003 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX).
Topics: Adolescent; Aging; Antioxidants; C-Peptide; Child; Diabetes Mellitus, Type 1; Drug Therapy, Combinat | 2004 |
[European Nicotinamide Diabetes Intervention Trial (ENDIT)--secondary publication. A randomized, placebo-controlled trial of intervention before the onset of type 1 diabetes].
Topics: Adolescent; Child; Child, Preschool; Diabetes Mellitus, Type 1; Double-Blind Method; Humans; Niacina | 2005 |
Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Creatinine; Diabetes Mellitus, Type 1; Glomerular Filtrati | 2005 |
A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus.
Topics: Adolescent; Adult; C-Peptide; Child; Diabetes Mellitus, Type 1; Drug Administration Schedule; Female | 2005 |
Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics.
Topics: Adolescent; Adult; Autoantibodies; Child; Child, Preschool; Chile; Diabetes Mellitus, Type 1; Diabet | 2006 |
Nicotinamide reduces high secretion of IFN-gamma in high-risk relatives even though it does not prevent type 1 diabetes.
Topics: Adolescent; Adult; Autoantigens; Child; Diabetes Mellitus, Type 1; Down-Regulation; Glutamate Decarb | 2006 |
Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes.
Topics: Adolescent; Adult; Autoantibodies; Blood Glucose; Child; Child, Preschool; Diabetes Mellitus, Type 1 | 2006 |
The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI).
Topics: Adolescent; Blood Glucose; Calcitriol; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; | 2006 |
Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).
Topics: Adolescent; Adult; Age Factors; Analysis of Variance; Blood Glucose; C-Peptide; Child; Child, Presch | 1995 |
Adjuvant therapy in recent onset type 1 diabetes at diagnosis and insulin requirement after 2 years.
Topics: Adjuvants, Pharmaceutic; Adolescent; Adult; Age of Onset; Child; Cyclosporine; Diabetes Mellitus, Ty | 1995 |
Residual B cell activity and insulin requirements in insulin-dependent diabetic patients treated from the beginning with high doses of nicotinamide. A two-year follow-up.
Topics: Adult; B-Lymphocytes; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; Humans; Insulin; Male; N | 1994 |
Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study.
Topics: Adolescent; Adult; Age Factors; Anti-Inflammatory Agents; C-Peptide; Child; Child, Preschool; Diabet | 1994 |
On the sequential design of the Deutsche Nikotinamid Interventionsstudie--DENIS.
Topics: Child; Child, Preschool; Diabetes Mellitus, Type 1; Double-Blind Method; Humans; Hypoglycemic Agents | 1993 |
Intervention with nicotinamide in pre-type 1 diabetes: the Deutsche Nikotinamid Interventionsstudie-DENIS.
Topics: Autoantibodies; Child; Child, Preschool; Diabetes Mellitus, Type 1; Follow-Up Studies; Germany; HLA- | 1993 |
Nicotinamide--biological actions and therapeutic potential in diabetes prevention. IDIG Workshop, Copenhagen, Denmark, 4-5 December 1992.
Topics: Animals; Denmark; Diabetes Mellitus, Type 1; Humans; Niacinamide; Poly(ADP-ribose) Polymerases; Pros | 1993 |
Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM.
Topics: Adult; Autoantibodies; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Family; Humans; Insulin | 1996 |
BCG vaccine in insulin-dependent diabetes mellitus. IMDIAB Group.
Topics: Adolescent; BCG Vaccine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Follow-Up Studies; Gly | 1997 |
Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study)
Topics: Adolescent; Adult; C-Peptide; Child; Child, Preschool; Diabetes Mellitus, Type 1; Glycated Hemoglobi | 1997 |
The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group.
Topics: Austria; Autoantibodies; Biomarkers; Body Constitution; Body Mass Index; Child; Child, Preschool; Di | 1998 |
Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes.
Topics: Adult; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Female; Glutamate Decarboxylase; Humans | 2000 |
[Genetic and immunologic risks for development of type 1 diabetes--experiences from an intervention trial].
Topics: Adult; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Genetic Markers; Genetic Predispositio | 2000 |
Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT).
Topics: Diabetes Mellitus, Type 1; Humans; Insulin; Mass Screening; Multicenter Studies as Topic; Niacinamid | 2001 |
Double-blind randomized trial of nicotinamide on early-onset diabetes.
Topics: Blood Glucose Self-Monitoring; C-Peptide; Diabetes Mellitus, Type 1; Double-Blind Method; Glycated H | 1992 |
Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide.
Topics: Autoantibodies; Biomarkers; Child; Diabetes Mellitus, Type 1; Follow-Up Studies; Humans; Insulin; In | 1991 |
A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus.
Topics: Adolescent; C-Peptide; Child; Clinical Trials as Topic; Delayed-Action Preparations; Diabetes Mellit | 1990 |
Effect of nicotinamide therapy upon B-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients.
Topics: Adolescent; Autoantibodies; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Female; | 1989 |
Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 1; Female; Glucagon; Glycated Hemoglobin; HLA-DR Antigens; | 1989 |
Nicotinamide may extend remission phase in insulin-dependent diabetes.
Topics: Administration, Oral; Adolescent; Adult; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 1; | 1987 |
62 other studies available for niacinamide and Autoimmune Diabetes
| Article | Year |
|---|---|
[Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®)].
Topics: Aged; Blood Glucose; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Humans; Hypoglyc | 2022 |
Nicotinamide Prevents Diabetic Brain Inflammation via NAD+-Dependent Deacetylation Mechanisms.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Encephalitis; Male; Mice; Mice, | 2023 |
Evaluation of hepatic CYP2D1 activity and hepatic clearance in type I and type II diabetic rat models, before and after treatment with insulin and metformin.
Topics: Animals; Cytochrome P450 Family 2; Dextromethorphan; Diabetes Mellitus, Experimental; Diabetes Melli | 2020 |
Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Endothelial C | 2019 |
Children at risk of diabetes type 1. Treatment with acetyl-L-carnitine plus nicotinamide - case reports.
Topics: Acetylcarnitine; Autoantibodies; Child; Child Development; Child, Preschool; Diabetes Mellitus, Type | 2013 |
Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of Type 1 diabetes.
Topics: Animals; Blood Platelets; Calcium; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Femal | 2013 |
Streptozotocin-Induced Diabetic Models in Mice and Rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet | 2015 |
Effects of Trigonelline, an Alkaloid Present in Coffee, on Diabetes-Induced Disorders in the Rat Skeletal System.
Topics: Alkaloids; Animals; Biomarkers; Bone Density; Coffea; Diabetes Complications; Diabetes Mellitus, Exp | 2016 |
Effect of nicotinamide on early graft failure following intraportal islet transplantation.
Topics: Animals; Blood Glucose; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; | 2009 |
Differentiation of mesenchymal stem cells to insulin-producing cells and their impact on type 1 diabetic rats.
Topics: Alloxan; Animals; Cell Differentiation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; | 2010 |
The role of autoantibodies to zinc transporter 8 in prediction of type 1 diabetes in relatives: lessons from the European Nicotinamide Diabetes Intervention Trial (ENDIT) cohort.
Topics: Adolescent; Adult; Autoantibodies; Cation Transport Proteins; Child; Cohort Studies; Diabetes Mellit | 2012 |
Growth inhibitors promote differentiation of insulin-producing tissue from embryonic stem cells.
Topics: Androstadienes; Animals; Biomarkers; Cell Aggregation; Cell Differentiation; Cell Line; Diabetes Mel | 2002 |
Niacinamide. Monograph.
Topics: Acute Disease; Animals; Anticonvulsants; Diabetes Mellitus, Type 1; Drug Interactions; Humans; Niaci | 2002 |
Clinical trials. Diabetes' brave new world.
Topics: Adolescent; Adult; Autoantibodies; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Disea | 2003 |
Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes.
Topics: Aging; Animals; Apoptosis; Diabetes Mellitus, Type 1; Enzyme Inhibitors; Interferon-gamma; Interleuk | 2003 |
[EFFECT OF SOME VITAMINS FROM THE B GROUP AND OF COCARBOXYLASE ON THE BLOOD SUGAR CURVE IN JUVENILE DIABETES MELLITUS].
Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 1; Folic Acid; Humans; Niacin; Niacinamide; Pharm | 1963 |
Growing pains in the pursuit of diabetes prevention.
Topics: Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Multicenter Studies as Topic; Niaci | 2004 |
Effects of long-term exposure to nicotinamide and sodium butyrate on growth, viability, and the function of clonal insulin secreting cells.
Topics: Animals; Butyrates; Cell Division; Cell Survival; Clone Cells; Diabetes Mellitus, Type 1; Glucose; I | 2004 |
Differentiation of human embryonic stem cells into insulin-producing clusters.
Topics: Apoptosis; Cell Culture Techniques; Cell Differentiation; Cells, Cultured; Diabetes Mellitus, Type 1 | 2004 |
Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats.
Topics: Animals; Blood Glucose; Cell Division; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; D | 2004 |
Diminished Th1-like response to autoantigens in children with a high risk of developing type 1 diabetes.
Topics: Adolescent; Adult; Autoantigens; C-Reactive Protein; Child; Diabetes Mellitus, Type 1; Enzyme-Linked | 2005 |
Nicotinamide trials in diabetes intervention. Does a metabolite provide benefit?
Topics: Diabetes Mellitus, Type 1; Humans; Niacinamide; Placebos; Randomized Controlled Trials as Topic | 2005 |
Effects of ingested fruiting bodies, submerged culture biomass, and acidic polysaccharide glucuronoxylomannan of Tremella mesenterica Retz.:Fr. on glycemic responses in normal and diabetic rats.
Topics: Agaricales; Animals; Biomass; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Dia | 2006 |
Effect of nicotinamide on newly diagnosed type 1 diabetic children.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug | 2006 |
Improved human islet isolation using nicotinamide.
Topics: Adenosine; Adult; Allopurinol; Cell Separation; Diabetes Mellitus, Type 1; Glutathione; Humans; Insu | 2006 |
The effects of calcitriol and nicotinamide on residual pancreatic beta-cell funtion in patients with recent-onset Type 1 diabetes (IMDIAB XI).
Topics: Calcitriol; Diabetes Mellitus, Type 1; Humans; Insulin-Secreting Cells; Niacinamide | 2007 |
Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Follow-Up Studies; Humans; Interleukin-2; Niaci | 2008 |
Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT).
Topics: Adolescent; Autoimmunity; Child; Cohort Studies; Diabetes Mellitus, Type 1; Disease Progression; Eur | 2008 |
New trends in diabetes research: the search for an etiologically oriented treatment for type I diabetes mellitus.
Topics: Animals; B-Lymphocytes; Diabetes Mellitus, Type 1; Diet, Diabetic; Disease Models, Animal; Humans; I | 1983 |
Hormonal and environmental factors in the pathogenesis of BB rat diabetes.
Topics: 3-O-Methylglucose; Animals; Body Weight; Castration; Diabetes Mellitus, Experimental; Diabetes Melli | 1983 |
Nicotinamide decreases nitric oxide production and partially protects human pancreatic islets against the suppressive effects of combinations of cytokines.
Topics: Adult; Diabetes Mellitus, Type 1; DNA; Drug Interactions; Humans; Insulin; Insulin Secretion; Interf | 1994 |
The design of trials for prevention of IDDM.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Glucose Tolerance Test; Humans; Insulin; Niacin | 1993 |
[Current technologies and strategies in the treatment of insulin-dependent diabetes mellitus].
Topics: Administration, Intranasal; Diabetes Mellitus, Type 1; Humans; Injections, Jet; Insulin; Insulin Inf | 1994 |
The use of nicotinamide in the prevention of type 1 diabetes.
Topics: Animals; Child; Child, Preschool; Diabetes Mellitus, Type 1; Female; Humans; Mice; Mice, Inbred NOD; | 1993 |
Preventing insulin dependent diabetes mellitus.
Topics: Diabetes Mellitus, Type 1; Diet; Family; Humans; Niacinamide; Risk Factors | 1993 |
[Prevention of juvenile diabetes (type 1): reality or fiction?].
Topics: Adolescent; Autoimmunity; Child; Child, Preschool; Cyclosporine; Diabetes Mellitus, Type 1; Humans; | 1994 |
A combined casein-free-nicotinamide diet prevents diabetes in the NOD mouse with minimum insulitis.
Topics: Animals; Caseins; Diabetes Mellitus, Type 1; Diet, Protein-Restricted; Female; Fluorescent Antibody | 1995 |
Differences in the expression of heat-shock proteins and antioxidant enzymes between human and rodent pancreatic islets: implications for the pathogenesis of insulin-dependent diabetes mellitus.
Topics: Adolescent; Adult; Aged; Animals; Antibody Specificity; Antioxidants; Apoptosis; Catalase; Child; Di | 1995 |
[Use of alpha-tocopherol acetate and nicotinamide at the onset of insulin dependent diabetes mellitus].
Topics: Adolescent; Adult; Antioxidants; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Islet | 1995 |
Effects of nicotinamide on prevention and treatment of streptozotocin-induced diabetes mellitus in rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Free Radical Scavengers | 1996 |
Inhibition of diabetes in non-obese diabetic mice by nicotinamide treatment for 5 weeks at the early age.
Topics: Age of Onset; Animals; Antioxidants; Diabetes Mellitus, Type 1; Female; Mice; Mice, Inbred NOD; Niac | 1997 |
IDDM preventive trials: what's new?
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diet; Humans; Insulin; Niacinamide; Nutritional | 1998 |
Oxygen radical production in human mononuclear blood cells is not suppressed by drugs used in clinical islet transplantation.
Topics: Diabetes Mellitus, Type 1; Humans; Immunosuppressive Agents; Interleukin-1; Islets of Langerhans Tra | 1999 |
Insulin increases in vitro production of Th2 profile cytokines in peripheral blood cultures in subjects at high risk of diabetes type 1 and patients with newly diagnosed IDDM.
Topics: Adolescent; Adult; Cells, Cultured; Cytokines; Diabetes Mellitus, Type 1; Female; Humans; Insulin; I | 1999 |
Nicotinamide inhibits enhanced in vitro production of interleukin-12 and tumour necrosis factor-alpha in peripheral whole blood of people at high risk of developing type 1 diabetes and people with newly diagnosed type 1 diabetes.
Topics: Adult; Autoantibodies; Cells, Cultured; Diabetes Mellitus, Type 1; Family; Female; Humans; Insulin; | 2000 |
Nicotinamide prevents the development of diabetes in the cyclophosphamide-induced NOD mouse model by reducing beta-cell apoptosis.
Topics: Animals; Apoptosis; Cyclophosphamide; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Is | 2000 |
Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse.
Topics: Adoptive Transfer; Adult; Animals; Autoantibodies; Autoimmune Diseases; Cell Transplantation; Clinic | 2001 |
Prevention of cyclophosphamide-induced accelerated diabetes in the NOD mouse by nicotinamide or a soy protein-based infant formula.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Diabetes Mellitus | 2001 |
Use of in vitro-generated, stem cell-derived islets to cure type 1 diabetes: how close are we?
Topics: Animals; Cell Culture Techniques; Cell Differentiation; Diabetes Mellitus, Type 1; Embryonic and Fet | 2002 |
IL-1beta expression in islet cells of the NOD mouse and its spatial relationship to beta cells and inducible nitric oxide synthase.
Topics: Animals; Cyclophosphamide; Diabetes Mellitus, Type 1; Enzyme Induction; Female; Gene Expression; Int | 2002 |
Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Humans; Insulin; Insulin Secretion; Islets of L | 1992 |
Nicotinamide and prevention of diabetes.
Topics: Diabetes Mellitus, Type 1; Family; Humans; Niacinamide | 1992 |
[Early intensification of treatment in diabetes using a combination of insulin and nicotinamide--effect on C-peptide levels and the course of the disease].
Topics: C-Peptide; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Insulin; Niacinamide | 1992 |
[Remission of diabetes mellitus].
Topics: Diabetes Mellitus, Type 1; Female; HLA Antigens; Humans; Immunosuppressive Agents; Insulin; Male; Ni | 1991 |
Diabetes, cyclosporin nephrotoxicity, and serum creatinine concentration.
Topics: Creatinine; Cyclosporins; Diabetes Mellitus, Type 1; Glomerular Filtration Rate; Humans; Kidney; Kid | 1991 |
The effects of type 1 diabetes mellitus and of tobacco smoke on dissipation of catecholamines in pulmonary endothelial cells--a non-neuronal site of uptake1.
Topics: Animals; Biological Transport; Catechol O-Methyltransferase; Diabetes Mellitus, Experimental; Diabet | 1991 |
Early nicotinamide treatment in the NOD mouse: effects on diabetes and insulitis suppression and autoantibody levels.
Topics: Animals; Autoantibodies; Diabetes Mellitus, Type 1; Female; Islets of Langerhans; Male; Mice; Mice, | 1990 |
Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide.
Topics: Administration, Oral; Autoantibodies; Autoimmune Diseases; Diabetes Mellitus, Type 1; Drug Evaluatio | 1989 |
Elevated antibody-dependent cell-mediated cytotoxicity and its inhibition by nicotinamide in the diabetic NOD mouse.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 1986 |
Nicotinamide treatment in diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Female; Humans; Necrobiosis Lipoidica; Niacinamide | 1987 |
High dose nicotinamide in the treatment of necrobiosis lipoidica.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Drug Administration Schedule; Female; Humans; Male; Middle A | 1988 |
[The action of nicotinamide on the adenine nucleotide system as well as on mitochondrial oxidation and phosphorylation processes in the liver of db/db strain mice].
Topics: Adenine Nucleotides; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 1; Mice; Mice, Inbred C57BL | 1988 |